제산제 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the antacids market size is projected to expand from USD 7.06 billion in 2025 and USD 7.30 billion in 2026 to USD 8.65 billion by 2031, registering a CAGR of 3.45% between 2026 to 2031.

This report is Segmented by Formulation Type (Tablets, Powders, and More), Active Ingredient Type (Calcium Carbonate, Alginate-Based, and More), Indication (Heartburn, Gastroesophageal Reflux Disease (GERD), and More), Distribution Channel (Hospital Pharmacies, E-Commerce, and More), Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Antacids Market Trends and Insights

Aging Population and Rising Gastrointestinal Disorder Incidence

Adults aged 65 and older will comprise 16% of the world's residents by 2030, and this demographic experiences gastroesophageal reflux disease at nearly twice the rate of younger cohorts, making them habitual purchasers in the antacids market. Japan already reports more than 29% of its population in the senior bracket, and per-capita antacid use there outpaces all other countries. European economies such as Italy and Germany will reach senior shares of roughly 28% by 2031, sustaining baseline demand even as prescription proton pump inhibitors (PPIs) address chronic reflux. Manufacturers are answering with lower-sodium liquids that accommodate hypertension management and with bundle packs that pair antacids with bone-health nutrients. Collectively, demographic tailwinds secure a dependable slice of the antacids market over the long term.

Unhealthy Dietary Habits and Sedentary Lifestyles

Urbanization across Asia-Pacific is amplifying consumption of high-fat convenience foods, pushing heartburn incidence upward and generating fresh demand in the antacids market. Obesity rates in China are on course to exceed 14% by 2025, while India's largest cities are recording functional dyspepsia prevalence near 20%. Producers have an untapped opportunity to localize formulations-such as adding herbal demulcents helpful against spicy cuisines-yet most brands continue to export global SKUs without regional tweaks, leaving room for domestic challengers.

Switch to Proton Pump Inhibitors and H2 Antagonists

United States PPIs exceed USD 4 billion in annual retail sales, reflecting physician preference for once-daily acid suppression and placing a ceiling on potential volume gains for the antacids market. Yet emerging safety concerns regarding chronic PPI use are nudging certain patients back toward intermittent antacids, creating a partial offset.

Other drivers and restraints analyzed in the detailed report include:

1. Over-the-Counter Accessibility and Self-Medication Culture
2. Microbiome-Focused Combination Research and Development
3. Safety Concerns with Chronic Antacid Use

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The antacids market size for tablets reached 41.56% of revenue in 2025, whereas gummies and chewable soft-gels are climbing at a 9.25% CAGR, the fastest within this segmentation. Gummies benefit from confectionery textures and the ability to layer sleep-enhancing melatonin, recasting antacid use as part of a broader nighttime routine. Meanwhile, liquids grow at 7.7% as pediatric and geriatric cohorts expand. Powders and effervescents remain small but stable, prized for rapid onset by travelers and sports enthusiasts.

Liquids face logistic cost pressure because packaging is heavier and more fragile, but their palatability gains when manufacturers employ taste-masking technology. Traditional tablets will likely keep the largest slice of the antacids market, yet their dominance erodes as millennials and Gen-Z age into higher gastric-symptom prevalence and import gummy preferences from adjacent supplement categories.

Calcium carbonate commanded 35.53% of 2025 revenue thanks to its dual benefit of neutralizing acid and delivering dietary calcium, but alginates are the standout growth engine at an 8.85% CAGR. The raft-forming mechanism resonates with consumers seeking drug-free solutions and differentiates brands such as Gaviscon. Magnesium and aluminum compounds maintain mid-tier status but face safety perceptions that limit heavy repeat use. Sodium bicarbonate remains a budget choice, useful for rapid, episodic relief yet hampered by high sodium content.

Combination products blend calcium with magnesium hydroxide or add simethicone to tackle bloating, appealing to functional dyspepsia sufferers. Raw-material cost is the primary brake on alginate roll-out because pharmaceutical-grade sodium alginate trades at a 50% premium to carbonate salts, but educational campaigns and growing clinician endorsement are beginning to justify the price differential inside the antacids market.

Complete Report Scope:

• By Formulation Type
  • Tablets
  • Liquids / Suspensions
  • Powders
  • Gummies / Chewable Soft-Gels
  • Effervescent Granules
  • Other Formulations
• By Active Ingredient Type
  • Calcium Carbonate
  • Magnesium Compounds
  • Aluminium Compounds
  • Sodium Bicarbonate
  • Alginate-Based
  • Combination Preparations
• By Indication
  • Heartburn
  • Gastroesophageal Reflux Disease (GERD)
  • Peptic Ulcer
  • Functional Dyspepsia
  • Other Acid-Related Disorders
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • E-Commerce
  • Other Channels
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America, at 39.53% of 2025 revenue, remains the largest territory in the antacids market because of high self-medication rates and fast product switching upon symptom onset. Unit volumes plateau as heavy PPI users emerge, but gummy and clean-label launches offset attrition. Canada and Mexico expand at mid-single-digit rates as cross-border e-commerce brings United States SKUs into previously insulated retail environments.

Asia-Pacific is the standout growth engine, forecast to add nearly USD 1 billion in incremental sales through 2031 at a 9.51% CAGR. Japan's unprecedented aging profile propels liquids and low-sodium variants, while China's streamlined over-the-counter rules shorten launch cycles for foreigners and domestic players alike. India illustrates urban-rural divergence: metropolitan dyspepsia prevalence hits 20%, yet price-sensitive rural consumers gravitate toward generic powders.

Europe sits in between, challenged by strict European Medicines Agency labeling and widespread PPI reimbursement. The United Kingdom follows a step-up protocol that begins with lifestyle modification and antacids, ensuring baseline demand. Brexit-related customs complexities inflate import costs, nudging some companies to regionalize manufacturing.

The Middle East, Africa, and South America together contribute a modest but rising share. Gulf Cooperation Council nations show obesity rates above 30%, stimulating heartburn complaints, yet e-commerce infrastructure is still developing. Brazil and Argentina remain volatile; currency swings push shoppers toward private-label products, favoring local contract manufacturers.

1. Abbott Laboratories
2. Adcock Ingram Holdings Ltd.
3. AdvaCare
4. Advance Pharmaceutical
5. Akums Drugs & Pharmaceuticals Ltd.
6. AstraZeneca
7. Bayer
8. CVS Health
9. Dr. Reddy's Laboratories
10. Haleon Plc
11. Johnson & Johnson (Kenvue)
12. Novartis
13. Perrigo Company
14. Pfizer
15. Procter & Gamble
16. Reckitt Benckiser Group
17. Sanofi
18. Sun Pharmaceuticals Industries
19. Takeda Pharmaceuticals
20. WellSpring Pharmaceutical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Aging population & rising GI disorder incidence
  • 4.2.2 Unhealthy dietary habits & sedentary lifestyles
  • 4.2.3 OTC accessibility & self-medication culture
  • 4.2.4 Expansion of retail pharmacy & e-commerce channels
  • 4.2.5 Microbiome-focused combination R&D
  • 4.2.6 Digital gut-symptom tracking partnerships
• 4.3 Market Restraints
  • 4.3.1 Switch to PPIs & H2 antagonists
  • 4.3.2 Safety concerns with chronic antacid use
  • 4.3.3 Volatile mineral-based raw-material supply
  • 4.3.4 ESG-driven aluminum footprint scrutiny
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Bargaining Power of Buyers
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Formulation Type
  • 5.1.1 Tablets
  • 5.1.2 Liquids / Suspensions
  • 5.1.3 Powders
  • 5.1.4 Gummies / Chewable Soft-Gels
  • 5.1.5 Effervescent Granules
  • 5.1.6 Other Formulations
• 5.2 By Active Ingredient Type
  • 5.2.1 Calcium Carbonate
  • 5.2.2 Magnesium Compounds
  • 5.2.3 Aluminium Compounds
  • 5.2.4 Sodium Bicarbonate
  • 5.2.5 Alginate-Based
  • 5.2.6 Combination Preparations
• 5.3 By Indication
  • 5.3.1 Heartburn
  • 5.3.2 Gastroesophageal Reflux Disease (GERD)
  • 5.3.3 Peptic Ulcer
  • 5.3.4 Functional Dyspepsia
  • 5.3.5 Other Acid-Related Disorders
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies & Drug Stores
  • 5.4.3 E-Commerce
  • 5.4.4 Other Channels
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Adcock Ingram Holdings Ltd.
  • 6.3.3 AdvaCare Pharma
  • 6.3.4 Advance Pharmaceutical Inc.
  • 6.3.5 Akums Drugs & Pharmaceuticals Ltd.
  • 6.3.6 AstraZeneca Plc
  • 6.3.7 Bayer AG
  • 6.3.8 CVS Health Corporation
  • 6.3.9 Dr. Reddy's Laboratories Ltd.
  • 6.3.10 Haleon Plc
  • 6.3.11 Johnson & Johnson (Kenvue)
  • 6.3.12 Novartis AG
  • 6.3.13 Perrigo Company Plc
  • 6.3.14 Pfizer Inc.
  • 6.3.15 Procter & Gamble Co.
  • 6.3.16 Reckitt Benckiser Group Plc
  • 6.3.17 Sanofi S.A.
  • 6.3.18 Sun Pharmaceutical Industries Ltd.
  • 6.3.19 Takeda Pharmaceutical Company Ltd.
  • 6.3.20 WellSpring Pharmaceutical Corporation

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment